On March 17, 2026 Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, reported that four abstracts highlighting the latest preclinical results from its pipeline programs have been selected for poster presentations at the American Association of Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2026, taking place April 17-22, 2026, in San Diego, CA, USA.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The data to be presented encompasses three of the Company’s novel drug candidates: BCR-ABL tyrosine kinase inhibitor Olverembatinib (HQP1351), FAK/ALK/ROS1 tyrosine kinase inhibitor APG-2449, and PRC2/EED inhibitor APG-5918.

The AACR (Free AACR Whitepaper) Annual Meeting 2026 is the critical driver of progress against cancer, the place where scientists, clinicians, other health care professionals, survivors, patients, and advocates gather to share and discuss the latest breakthroughs. From population science and prevention; to cancer biology, translational, and clinical studies; to survivorship and advocacy; the AACR (Free AACR Whitepaper) Annual Meeting showcases cutting-edge cancer science and medicine.

The four preclinical abstracts from Ascentage Pharma include:

Multitarget kinase inhibitor olverembatinib (HQP1351) is efficacious and synergizes with chemotherapy in preclinical models of endometrial carcinoma (EC)

Abstract#: 4583
Poster Session Category: Experimental and Molecular Therapeutics
Session Title: Novel Antitumor Agents 2
Time: Tuesday, April 21, 2026, 9:00 AM – 12:00 PM PDT

Multikinase inhibitor olverembatinib (HQP1351) is efficacious and synergizes with BTK inhibitor acalabrutinib in mantle cell lymphoma (MCL) preclinical models

Abstract#: 5875
Poster Session Category: Experimental and Molecular Therapeutics
Session Title: Tyrosine Kinase, Phosphatase, and Other Inhibitors
Time: Tuesday, April 21, 2026, 2:00 PM – 5:00 PM PDT

FAK inhibition by APG-2449 enhances the antitumor activity of MAPK pathway blockade in BRAF V600E-mutant tumor models

Abstract#: 1858
Poster Session Category: Experimental and Molecular Therapeutics
Session Title: Targeting Drug Resistance 1: Apoptosis and Autophagy
Time: Monday, April 20, 2026, 9:00 AM – 12:00 PM PDT

Embryonic ectoderm development (EED) inhibitor APG-5918 synergizes with topoisomerase I inhibitors in preclinical small-cell lung cancer (SCLC) models through epigenetic priming of chemosensitivity

Abstract#: 4500
Poster Session Category: Experimental and Molecular Therapeutics
Session Title: Epigenetic Modulators 1
Time: Tuesday, April 21, 2026, 9:00 AM – 12:00 PM PDT

*Olverembatinib, APG-2449, and APG-5918 are currently under investigation and have not been approved by the U.S. FDA.

(Press release, Ascentage Pharma, MAR 17, 2026, View Source [SID1234663657])